Bettina Kulle Andreassen

Bettina is working on several research projects within pharmacoepidemiology as for example the evaluation of prescription drugs and cancer risk and cancer survival by using advanced statistical and epidemiological methods.

In a recent registry-based «screening study», we evaluated the association between all prescription drugs and all cancer types.

Bettina is also interested in urological cancer types and is the supervisor for several PhD students and a PostDoc in clinical cancerepidemiological studies.

She investigates for example the disease-course of bladder cancer patients focussing on treatment management, progression and survival and the use of new drugs for cancer treatment in advanced prostate cancer patients.

From before, Bettina has a lot of experience with genetic and epigenetic epidemiological studies.

Bettina has a mandate at the directory of health (Handlingsplangruppe for blære- og urotelkreft). 


Bettina is a statistician with a PhD from the University of Göttingen, Germany.

Before she started working at the cancer registry in 2015, she was an Associate Professor at the University of Oslo. ​

Selected publications

Andreassen BK, Støer NC, Martinsen JI, Ursin G, Weiderpass E, Thoresen GH, Debernard KB, Karlstad Ø, Pottegard A, Friis S (2019) Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry-based study BMJ Open, 9 (4), e028504 DOI 10.1136/bmjopen-2018-028504, PubMed 30962244 

Page CM, Vos L, Rounge TB, Harbo HF, Andreassen BK (2018)
Assessing genome-wide significance for the detection of differentially methylated regions
Stat Appl Genet Mol Biol, 17 (5)
DOI 10.1515/sagmb-2017-0050, PubMed 30231014 

LeBlanc M, Zuber V, Thompson WK, Andreassen OA, Schizophrenia and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium, Frigessi A, Andreassen BK (2018)
A correction for sample overlap in genome-wide association studies in a polygenic pleiotropy-informed framework
BMC Genomics, 19 (1), 494
DOI 10.1186/s12864-018-4859-7, PubMed 29940862 

Andreassen BK, Grimsrud TK, Haug ES (2018). Bladder cancer survival: Women better off in the long run. Eur J Cancer 95:52-58. DOI 10.1016/j.ejca.2018.03.001 PubMed 29635144 

Andreassen BK, Myklebust TÅ, Haug ES (2017)
Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway
Scand J Urol, 51 (1), 38-43
DOI 10.1080/21681805.2016.1271354, PubMed 28084860


See all publications